JP5701603B2 - Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ - Google Patents

Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ Download PDF

Info

Publication number
JP5701603B2
JP5701603B2 JP2010524249A JP2010524249A JP5701603B2 JP 5701603 B2 JP5701603 B2 JP 5701603B2 JP 2010524249 A JP2010524249 A JP 2010524249A JP 2010524249 A JP2010524249 A JP 2010524249A JP 5701603 B2 JP5701603 B2 JP 5701603B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
stat3
item
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010524249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539097A (ja
JP2010539097A5 (enExample
Inventor
チャン チア リー，
チャン チア リー，
チーウェイ チャン，
チーウェイ チャン，
ハリー ロゴフ，
ハリー ロゴフ，
ユーチー リー，
ユーチー リー，
チーフェン リュー，
チーフェン リュー，
リ，　ウェイ
ウェイ リ，
Original Assignee
ボストン バイオメディカル， インコーポレイテッド
ボストン バイオメディカル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボストン バイオメディカル， インコーポレイテッド, ボストン バイオメディカル， インコーポレイテッド filed Critical ボストン バイオメディカル， インコーポレイテッド
Publication of JP2010539097A publication Critical patent/JP2010539097A/ja
Publication of JP2010539097A5 publication Critical patent/JP2010539097A5/ja
Application granted granted Critical
Publication of JP5701603B2 publication Critical patent/JP5701603B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
JP2010524249A 2007-09-10 2008-09-10 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ Expired - Fee Related JP5701603B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US60/971,144 2007-09-10
US1337207P 2007-12-13 2007-12-13
US61/013,372 2007-12-13
PCT/US2008/075903 WO2009036099A1 (en) 2007-09-10 2008-09-10 A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014177908A Division JP5925849B2 (ja) 2007-09-10 2014-09-02 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ

Publications (3)

Publication Number Publication Date
JP2010539097A JP2010539097A (ja) 2010-12-16
JP2010539097A5 JP2010539097A5 (enExample) 2014-01-23
JP5701603B2 true JP5701603B2 (ja) 2015-04-15

Family

ID=40452461

Family Applications (16)

Application Number Title Priority Date Filing Date
JP2010524249A Expired - Fee Related JP5701603B2 (ja) 2007-09-10 2008-09-10 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2010524251A Expired - Fee Related JP5872160B2 (ja) 2007-09-10 2008-09-10 癌治療のための新規の組成物および方法
JP2010524243A Expired - Fee Related JP5688840B2 (ja) 2007-09-10 2008-09-10 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014177915A Expired - Fee Related JP5938072B2 (ja) 2007-09-10 2014-09-02 癌治療のための新規の組成物および方法
JP2014177908A Expired - Fee Related JP5925849B2 (ja) 2007-09-10 2014-09-02 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2014232396A Expired - Fee Related JP6106149B2 (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014232397A Withdrawn JP2015034179A (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2015230291A Expired - Fee Related JP6358659B2 (ja) 2007-09-10 2015-11-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016004076A Expired - Fee Related JP6347795B2 (ja) 2007-09-10 2016-01-13 癌治療のための新規の組成物および方法
JP2016016973A Expired - Fee Related JP6346628B2 (ja) 2007-09-10 2016-02-01 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016097607A Withdrawn JP2016147906A (ja) 2007-09-10 2016-05-16 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2017242778A Withdrawn JP2018076349A (ja) 2007-09-10 2017-12-19 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2018102234A Withdrawn JP2018131464A (ja) 2007-09-10 2018-05-29 癌治療のための新規の組成物および方法
JP2019029436A Pending JP2019073560A (ja) 2007-09-10 2019-02-21 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2020085065A Pending JP2020117547A (ja) 2007-09-10 2020-05-14 癌治療のための新規の組成物および方法
JP2020091326A Pending JP2020143135A (ja) 2007-09-10 2020-05-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ

Family Applications After (15)

Application Number Title Priority Date Filing Date
JP2010524251A Expired - Fee Related JP5872160B2 (ja) 2007-09-10 2008-09-10 癌治療のための新規の組成物および方法
JP2010524243A Expired - Fee Related JP5688840B2 (ja) 2007-09-10 2008-09-10 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014177915A Expired - Fee Related JP5938072B2 (ja) 2007-09-10 2014-09-02 癌治療のための新規の組成物および方法
JP2014177908A Expired - Fee Related JP5925849B2 (ja) 2007-09-10 2014-09-02 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2014232396A Expired - Fee Related JP6106149B2 (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2014232397A Withdrawn JP2015034179A (ja) 2007-09-10 2014-11-17 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2015230291A Expired - Fee Related JP6358659B2 (ja) 2007-09-10 2015-11-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016004076A Expired - Fee Related JP6347795B2 (ja) 2007-09-10 2016-01-13 癌治療のための新規の組成物および方法
JP2016016973A Expired - Fee Related JP6346628B2 (ja) 2007-09-10 2016-02-01 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2016097607A Withdrawn JP2016147906A (ja) 2007-09-10 2016-05-16 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2017242778A Withdrawn JP2018076349A (ja) 2007-09-10 2017-12-19 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2018102234A Withdrawn JP2018131464A (ja) 2007-09-10 2018-05-29 癌治療のための新規の組成物および方法
JP2019029436A Pending JP2019073560A (ja) 2007-09-10 2019-02-21 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
JP2020085065A Pending JP2020117547A (ja) 2007-09-10 2020-05-14 癌治療のための新規の組成物および方法
JP2020091326A Pending JP2020143135A (ja) 2007-09-10 2020-05-26 Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ

Country Status (14)

Country Link
US (12) US9732055B2 (enExample)
EP (6) EP3050566B1 (enExample)
JP (16) JP5701603B2 (enExample)
CN (6) CN105963289B (enExample)
CA (4) CA2736564A1 (enExample)
CY (3) CY1117604T1 (enExample)
DK (4) DK2194987T3 (enExample)
ES (3) ES2584904T3 (enExample)
HR (3) HRP20160625T1 (enExample)
HU (3) HUE027657T2 (enExample)
PL (4) PL2194987T3 (enExample)
PT (2) PT2200431T (enExample)
SI (3) SI2200431T1 (enExample)
WO (3) WO2009036101A1 (enExample)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
SI2200431T1 (sl) * 2007-09-10 2016-10-28 Boston Biomedical, Inc. Sestave in metode za zdravljenje raka
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
DK2656844T3 (en) 2008-06-17 2015-03-02 Wyeth Llc ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
KR20110033922A (ko) 2008-07-08 2011-04-01 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 전사의 신호 변환자 및 활성제（ｓｔａｔｓ）의 증식 및 활성화의 신규한 억제제
ES2614912T3 (es) 2008-08-04 2017-06-02 Wyeth Llc Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina
EP2370082A4 (en) * 2008-12-01 2012-05-30 Univ Central Florida Res Found FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
US20130129675A1 (en) * 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
JP5794922B2 (ja) * 2009-12-28 2015-10-14 一般社団法人ファルマバレープロジェクト支援機構 １，３，４−オキサジアゾール−２−カルボキサミド化合物
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
JP6017964B2 (ja) 2010-03-01 2016-11-02 ティーエーユー・セラピューティクス・エルエルシー 癌診断および撮像
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
BR112012023661A2 (pt) * 2010-03-19 2020-11-24 Boston Biomedical, Inc. novos compostos e novas composições direcionadas a células-tronco cancerosas
CN106860443A (zh) * 2010-03-19 2017-06-20 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
AU2011227023B2 (en) * 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
WO2012024818A1 (en) * 2010-08-24 2012-03-01 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Novel anphthoquinones for disease therapies
US20130236473A1 (en) * 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
EP2643001A4 (en) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
CA2812348A1 (en) * 2010-11-30 2012-06-07 London Health Sciences Centre Research Inc. Egfr antagonist for the treatment of heart disease
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
WO2012170439A1 (en) * 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
SG10201601917XA (en) * 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
WO2013071163A2 (en) * 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP2814480A4 (en) * 2012-02-17 2015-10-28 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co Ltd PROCESS FOR THE PREPARATION OF AQUEOUS SUSPENSIONS OF NANOPARTICLES OF 4,9-DIHYDROXY-NAPHTO [2,3-B] FURANE ALIPHATIC ACID ESTERS DERIVATIVES
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
CN103705926A (zh) * 2012-10-08 2014-04-09 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US20160030384A1 (en) * 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
CA2910855C (en) * 2013-04-29 2024-04-02 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6472096B2 (ja) 2014-01-27 2019-02-20 ボストン バイオメディカル， インコーポレイテッド 癌を処置するための新規方法
WO2015120304A1 (en) * 2014-02-07 2015-08-13 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
WO2015120436A2 (en) 2014-02-10 2015-08-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 phosphorylation during graft-versus-host disease
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
WO2015171985A1 (en) * 2014-05-09 2015-11-12 The Brigham And Women's Hospital, Inc. Treatment of igg-immune complex-mediated organ damage
EP3153508B1 (en) 2014-06-09 2020-03-18 Kyoto Pharmaceutical Industries, Ltd. Naphthofuran derivatives for use as anticancer agents
CN107072984B (zh) * 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN107635991B (zh) 2015-01-08 2021-01-01 美国政府健康及人类服务部 作为tdp2的抑制剂的呋喃并喹啉二酮
EP3274346A1 (en) 2015-03-27 2018-01-31 Boston Biomedical, Inc. Water-soluble prodrugs
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
CN107708700A (zh) 2015-04-17 2018-02-16 波士顿生物医药有限公司 用于治疗癌症的方法
CA2983010A1 (en) * 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
EP3283070A1 (en) * 2015-04-17 2018-02-21 Boston Biomedical, Inc. Methods for treating cancer
US20180250261A1 (en) * 2015-04-27 2018-09-06 Boston Biomedical, Inc. Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
CN107835687A (zh) * 2015-05-14 2018-03-23 努卡那有限公司 癌症治疗
CN108012529A (zh) * 2015-05-15 2018-05-08 诺华股份有限公司 治疗egfr突变的癌症的方法
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
WO2017013865A1 (ja) 2015-07-17 2017-01-26 大日本住友製薬株式会社 ２－アセチル－４Ｈ，９Ｈ－ナフト［２，３－ｂ］フラン－４，９－ジオンの製造方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
CA2998469C (en) 2015-09-14 2025-12-09 Twelve Therapeutics, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
KR20180063075A (ko) 2015-10-05 2018-06-11 뉴카나 피엘씨 조합 요법
WO2017120439A1 (en) * 2016-01-07 2017-07-13 Virginia Commonwealth University A method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
WO2017151625A1 (en) * 2016-03-01 2017-09-08 Academia Sinica 4,9-dioxo-4,9-dihydronaphtho(2,3-b)furan-3-carboxmide derivatives and uses thereof for treating proliferative diseases and infectious diseases
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
WO2017164379A1 (ja) 2016-03-25 2017-09-28 大日本住友製薬株式会社 ２－アルキルカルボニルナフト［２，３－ｂ］フラン－４，９－ジオンの関連物質の製造方法、及びその関連物質
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018096401A1 (en) 2016-11-22 2018-05-31 Hitoshi Ban New naphtho[2,3-b]furan derivatives
CA3045306A1 (en) * 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
MX2019006326A (es) * 2016-11-30 2019-07-12 Tyme Inc Derivados de tirosina y composiciones que los comprenden.
EP3572082A4 (en) * 2017-01-22 2021-01-06 Jiangsu Hengrui Medicine Co., Ltd. USE OF EGFR / HER2 INHIBITOR IN COMBINATION WITH PYRIMIDINE-LIKE ANTIMETABOLIC DRUG
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
JP7604099B2 (ja) * 2017-06-04 2024-12-23 ラパポート・ファミリー・インスティテュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシーズ 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
CN111132614A (zh) * 2017-07-20 2020-05-08 路易斯安娜州立大学监测委员会，农业和机械学院 使用脉冲磁场梯度对恶性癌细胞的靶向渗透裂解
JPWO2019059344A1 (ja) 2017-09-22 2020-11-26 大日本住友製薬株式会社 化学活性化型水溶性プロドラッグ
KR20200088831A (ko) * 2017-11-16 2020-07-23 티르노보 리미티드 암 치료용 irs/stat3 이중 조절제 및 항 pd-1/pd-l1 항체의 조합물
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
EP3733840A4 (en) * 2017-12-28 2021-11-24 Kaneka Corporation INHIBITOR OF PLURIPOTENT STEM CELL AGGREGATION
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
BR112020017481A8 (pt) * 2018-03-20 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Derivados de di-hidrocromeno
PL3773537T3 (pl) * 2018-04-19 2022-05-23 Tvardi Therapeutics, Inc. Inhibitory stat3
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
AU2019341976A1 (en) * 2018-09-18 2021-04-15 General Incorporated Association Pharma Valley Project Supporting Organization Cancer combination therapy using quinoline carboxamide derivative
EA202190771A1 (ru) * 2018-10-12 2021-09-07 1Глоуб Биомедикал Ко., Лтд. Новое комбинированное решение для лечения рака, резистентного к химиотерапии
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020207344A1 (zh) * 2019-04-09 2020-10-15 健艾仕生物医药有限公司 匹莫齐特和甲氨蝶呤的药物组合及其应用
US11564913B2 (en) * 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
JPWO2020251015A1 (enExample) * 2019-06-14 2020-12-17
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
WO2021089791A1 (en) * 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021101902A1 (en) * 2019-11-20 2021-05-27 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学系统董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN115135326B (zh) * 2020-03-16 2024-09-13 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
EP4149667A4 (en) * 2020-05-11 2024-06-19 Purdue Research Foundation LOMUSTINE SCALE SYNTHESIS UNDER CONTINUOUS FLOW CONDITIONS
WO2022022524A1 (en) * 2020-07-27 2022-02-03 Huazhong University Of Science & Technology Prevention and/or treatment of a disease associated with stat3
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
DE69131856T2 (de) * 1990-07-10 2000-06-15 Canon K.K., Tokio/Tokyo Lichtempfindliches elektrophotographisches Element
TW252136B (enExample) 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
CA2361621A1 (en) 1999-01-27 2000-08-03 Richard Jove Inhibition of stat3 signal transduction for human cancer therapy
DE60042968D1 (de) * 1999-04-01 2009-10-29 Hana Biosciences Inc Zusammensetzungen und methoden zur behandlung lymphoma
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
EP1206436B1 (en) * 1999-08-02 2004-10-13 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
JP2001097860A (ja) * 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US7998947B2 (en) * 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2002351177A1 (en) 2001-11-29 2003-06-10 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
AU2003217961B2 (en) * 2002-03-08 2008-02-28 Signal Pharmaceuticals, Llc Combination therapy for treating, preventing or managing proliferative disorders and cancers
ES2271515T3 (es) 2002-03-15 2007-04-16 Natimmune A/S Composiciones farmaceuticas que comprenden lecitina de union a manosa.
WO2004024145A1 (en) 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
EP1551392A4 (en) * 2002-09-17 2006-09-20 Arqule Inc NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
TWI323662B (en) 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005016946A2 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
WO2005056055A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF PROTECTING AGAINST RADIATION USING INDUCERS OF NF-κB
JP4751336B2 (ja) 2003-12-11 2011-08-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 細胞増殖性疾患を治療する化合
DE10359828A1 (de) 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
EP1748772A2 (en) 2004-04-09 2007-02-07 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) * 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
EP1768977A2 (en) * 2004-07-02 2007-04-04 ICOS Corporation Compounds useful for inhibiting chk1
DE602005017283D1 (de) * 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
WO2006052712A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor
WO2006056399A2 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
EP1853242A4 (en) * 2005-02-25 2009-11-18 Univ Michigan LOW MOLECULAR STAT3 INHIBITORS AND THEIR USES
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
JPWO2006126505A1 (ja) 2005-05-26 2008-12-25 国立大学法人 東京大学 Ｓｔａｔ機能阻害剤およびその応用
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
CA2625219A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
BRPI0620624A2 (pt) * 2005-12-24 2011-11-16 Biotica Tech Ltd análogo de 21-deóximacbecina ou um sal farmaceuticamente aceitável do mesmo, método para a produção do mesmo, composição farmacêutica, cepas hospedeira e engenheirada, e, uso das mesmas
US20090012075A1 (en) * 2006-01-12 2009-01-08 Miller Thomas A Fluorinated Arylamide Derivatives
EP2001438A2 (en) * 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070243192A1 (en) 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
US20090286772A1 (en) * 2006-02-24 2009-11-19 Anh Chau 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
RU2456265C2 (ru) 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
SI2200431T1 (sl) * 2007-09-10 2016-10-28 Boston Biomedical, Inc. Sestave in metode za zdravljenje raka
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
BR112012023661A2 (pt) 2010-03-19 2020-11-24 Boston Biomedical, Inc. novos compostos e novas composições direcionadas a células-tronco cancerosas
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
AU2011227023B2 (en) 2010-03-19 2015-05-28 Boston Biomedical, Inc. Novel methods for targeting cancer stem cells
CN106860443A (zh) 2010-03-19 2017-06-20 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
US9150530B2 (en) 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
EP3283070A1 (en) 2015-04-17 2018-02-21 Boston Biomedical, Inc. Methods for treating cancer
CA2983010A1 (en) 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
CN107708700A (zh) 2015-04-17 2018-02-16 波士顿生物医药有限公司 用于治疗癌症的方法
US20180250261A1 (en) 2015-04-27 2018-09-06 Boston Biomedical, Inc. Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Also Published As

Publication number Publication date
JP2014221843A (ja) 2014-11-27
US20190263768A1 (en) 2019-08-29
JP6358659B2 (ja) 2018-07-18
JP6106149B2 (ja) 2017-03-29
EP2190429A1 (en) 2010-06-02
WO2009036059A2 (en) 2009-03-19
JP2016094465A (ja) 2016-05-26
EP3050566A2 (en) 2016-08-03
SI2200431T1 (sl) 2016-10-28
EP2200431A1 (en) 2010-06-30
JP6346628B2 (ja) 2018-06-20
JP5872160B2 (ja) 2016-03-01
CN101854930A (zh) 2010-10-06
JP2018131464A (ja) 2018-08-23
US20210115006A1 (en) 2021-04-22
EP2200431A4 (en) 2011-12-21
US20210024482A1 (en) 2021-01-28
CY1117604T1 (el) 2017-04-26
CN101854802A (zh) 2010-10-06
ES2584904T3 (es) 2016-09-30
JP2018076349A (ja) 2018-05-17
CA2736532A1 (en) 2009-03-19
EP3067054B1 (en) 2020-12-30
DK2190429T3 (en) 2016-05-30
HK1148942A1 (zh) 2011-09-23
EP2190429B1 (en) 2016-04-20
EP2190429A4 (en) 2011-12-14
CN105963289A (zh) 2016-09-28
CN101854937A (zh) 2010-10-06
US20180030022A1 (en) 2018-02-01
EP3058941A1 (en) 2016-08-24
JP2016147906A (ja) 2016-08-18
HRP20160949T1 (hr) 2016-10-07
CN104586832B (zh) 2018-02-16
WO2009036101A1 (en) 2009-03-19
US20150018410A1 (en) 2015-01-15
HK1148943A1 (en) 2011-09-23
ES2583010T3 (es) 2016-09-16
JP2016065101A (ja) 2016-04-28
JP2010539097A (ja) 2010-12-16
JP2016034976A (ja) 2016-03-17
US9732055B2 (en) 2017-08-15
US20200039948A1 (en) 2020-02-06
WO2009036099A1 (en) 2009-03-19
CN101854802B (zh) 2014-12-03
JP5925849B2 (ja) 2016-05-25
US20110112180A1 (en) 2011-05-12
SI2190429T1 (sl) 2016-10-28
CA2911990C (en) 2018-03-20
CN101854937B (zh) 2013-03-27
CN103288787B (zh) 2016-08-03
EP3050566A3 (en) 2016-11-30
HUE029111T2 (en) 2017-02-28
JP5688840B2 (ja) 2015-03-25
CN104586832A (zh) 2015-05-06
SI2194987T1 (sl) 2016-10-28
CN103288787A (zh) 2013-09-11
EP2200431B1 (en) 2016-07-20
EP2194987A2 (en) 2010-06-16
JP2015034179A (ja) 2015-02-19
HK1148906A1 (en) 2011-09-23
DK3050566T3 (en) 2019-03-11
JP2010539095A (ja) 2010-12-16
EP2194987A4 (en) 2011-11-30
WO2009036059A3 (en) 2009-07-02
CA2736563A1 (en) 2009-03-19
JP2019073560A (ja) 2019-05-16
CY1117833T1 (el) 2017-05-17
HUE027657T2 (en) 2016-11-28
CA2736564A1 (en) 2009-03-19
US10377731B2 (en) 2019-08-13
DK2200431T3 (en) 2016-08-15
JP2014231522A (ja) 2014-12-11
JP6347795B2 (ja) 2018-06-27
CA2736532C (en) 2018-03-20
HRP20160625T1 (hr) 2016-08-12
US20170197932A1 (en) 2017-07-13
CN101854930B (zh) 2016-05-04
EP3067054A1 (en) 2016-09-14
PL2190429T3 (pl) 2016-09-30
JP2015038151A (ja) 2015-02-26
JP2020143135A (ja) 2020-09-10
ES2569215T3 (es) 2016-05-09
CY1118476T1 (el) 2017-07-12
EP2194987B1 (en) 2016-05-18
JP2010539098A (ja) 2010-12-16
EP3058941B1 (en) 2019-05-22
US20100310503A1 (en) 2010-12-09
US8877803B2 (en) 2014-11-04
CA2736563C (en) 2016-01-26
CN105963289B (zh) 2021-02-26
HUE027443T2 (en) 2016-10-28
PL2200431T3 (pl) 2017-01-31
PT2200431T (pt) 2016-08-03
US20180030021A1 (en) 2018-02-01
US10851075B2 (en) 2020-12-01
EP3050566B1 (en) 2018-11-28
US20120252763A1 (en) 2012-10-04
US9834532B2 (en) 2017-12-05
DK2194987T3 (en) 2016-08-15
PL2194987T3 (pl) 2017-01-31
JP5938072B2 (ja) 2016-06-22
US20190135773A1 (en) 2019-05-09
PL3067054T3 (pl) 2021-10-04
JP2020117547A (ja) 2020-08-06
US9745278B2 (en) 2017-08-29
PT2194987T (pt) 2016-08-05
CA2911990A1 (en) 2009-03-19
HRP20160430T1 (hr) 2016-05-20

Similar Documents

Publication Publication Date Title
JP6346628B2 (ja) Ｓｔａｔ３経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
JP2010539097A5 (enExample)
ES2713455T3 (es) Un grupo novedoso de inhibidores de la ruta STAT3 e inhibidores de la ruta de células madre de cáncer
HK1229259B (zh) 一类stat3通路抑制剂和癌干细胞通路抑制剂
HK1227310B (en) A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
HK1227310A1 (en) A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
HK1229259A1 (en) A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
HK1229259A (en) A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
HK1148942B (en) A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
HK1148906B (en) Compositions and methods for cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130903

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140902

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140922

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150218

R150 Certificate of patent or registration of utility model

Ref document number: 5701603

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees